et0111
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 30, 2022 (NCT05522309)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fibroblast growth factor receptor 3INHIBITOR
FGFR3 inhibitor
- Fibroblast growth factor receptor 2INHIBITOR
FGFR2 inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05522309 | Phase 1 | Aug 30, 2022 | Etern BioPharma (Shanghai) Co., Ltd, People's Liberation Army of China |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Etern BioPharma (Shanghai) Co., Ltd | For profit | 1 | 1 | 1 | 2022 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1